New Analysis Clouds Lurasidone’s Japan Schizophrenia Prospects
This article was originally published in PharmAsia News
The future of Sumitomo Dainippon Pharma's atypical antipsychotic Latuda (lurasidone) in Japan for its main indication of schizophrenia has been thrown into doubt by a deeper analysis of Phase III results.
You may also be interested in...
Takeda is confident about the promise of its first-in-class molecule for higher-risk myelodysplastic syndromes after positive Phase II data.
While Xtandi has positive new survival data in prostate cancer, other rivals in the competitive market are reporting the same at ASCO.
Join Scrip and the Pink Sheet’s Asia content team for a wide-ranging look at the ongoing multiple impacts of the pandemic on the pharma industry.